{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T15:43:45Z","timestamp":1762875825499},"reference-count":19,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2017,2,1]],"date-time":"2017-02-01T00:00:00Z","timestamp":1485907200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","jdcjournal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Diabetes and its Complications"],"published-print":{"date-parts":[[2017,2]]},"DOI":"10.1016\/j.jdiacomp.2016.08.017","type":"journal-article","created":{"date-parts":[[2016,9,9]],"date-time":"2016-09-09T20:01:58Z","timestamp":1473451318000},"page":"517-519","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Following the LEADER \u2013 why this and other recent trials signal a major paradigm shift in the management of type 2 diabetes"],"prefix":"10.1016","volume":"31","author":[{"given":"Mikhail","family":"Kosiborod","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jdiacomp.2016.08.017_bb0005","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1056\/NEJMoa1001286","article-title":"Effects of intensive blood-pressure control in type 2 diabetes mellitus","volume":"362","author":"Cushman","year":"2010","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.jdiacomp.2016.08.017_bb0010","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1056\/NEJMoa0808431","article-title":"Glucose control and vascular complications in veterans with type 2 diabetes","volume":"360","author":"Duckworth","year":"2009","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.jdiacomp.2016.08.017_bb0015","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa0802743","article-title":"Effects of intensive glucose lowering in type 2 diabetes","volume":"358","author":"Gerstein","year":"2008","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.jdiacomp.2016.08.017_bb0020","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1056\/NEJMoa1006524","article-title":"Long-term effects of intensive glucose lowering on cardiovascular outcomes","volume":"364","author":"Gerstein","year":"2011","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.jdiacomp.2016.08.017_bb0025","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1056\/NEJMoa1001282","article-title":"Effects of combination lipid therapy in type 2 diabetes mellitus","volume":"362","author":"Ginsberg","year":"2010","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.jdiacomp.2016.08.017_bb0030","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1056\/NEJMoa1414266","article-title":"Follow-up of glycemic control and cardiovascular outcomes in type 2 diabetes","volume":"372","author":"Hayward","year":"2015","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.jdiacomp.2016.08.017_bb0035","first-page":"2479","article-title":"Sitagliptin and cardiovascular outcomes in type 2 diabetes","volume":"373","author":"Holman","year":"2015","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.jdiacomp.2016.08.017_bb0040","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1056\/NEJMoa0806470","article-title":"10-year follow-up of intensive glucose control in type 2 diabetes","volume":"359","author":"Holman","year":"2008","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.jdiacomp.2016.08.017_bb0045","doi-asserted-by":"crossref","first-page":"140","DOI":"10.2337\/dc14-2441","article-title":"Management of hyperglycemia in type 2 diabetes, 2015: A patient-centered approach: Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes","volume":"38","author":"Inzucchi","year":"2015","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2016.08.017_bb0050","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1056\/NEJMoa1506930","article-title":"Pioglitazone after ischemic stroke or transient ischemic attack","volume":"374","author":"Kernan","year":"2016","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.jdiacomp.2016.08.017_bb0055","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.jdiacomp.2016.08.017_bb0060","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1001\/jama.2014.16107","article-title":"Association between 7years of intensive treatment of type 1 diabetes and long-term mortality","volume":"313","author":"Orchard","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.jdiacomp.2016.08.017_bb0065","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1056\/NEJMoa0802987","article-title":"Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes","volume":"358","author":"Patel","year":"2008","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.jdiacomp.2016.08.017_bb0070","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1056\/NEJMoa1509225","article-title":"Lixisenatide in patients with type 2 diabetes and acute coronary syndrome","volume":"373","author":"Pfeffer","year":"2015","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.jdiacomp.2016.08.017_bb0075","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1056\/NEJMoa1307684","article-title":"Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus","volume":"369","author":"Scirica","year":"2013","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.jdiacomp.2016.08.017_bb0080","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1515920","article-title":"Empagliflozin and progression of kidney disease in type 2 diabetes","volume":"375","author":"Wanner","year":"2016","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.jdiacomp.2016.08.017_bb0085","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1056\/NEJMoa1305889","article-title":"Alogliptin after acute coronary syndrome in patients with type 2 diabetes","volume":"369","author":"White","year":"2013","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.jdiacomp.2016.08.017_bb0090","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1056\/NEJMoa1212914","article-title":"Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes","volume":"369","author":"Wing","year":"2013","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.jdiacomp.2016.08.017_bb0095","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"The New England Journal of Medicine"}],"container-title":["Journal of Diabetes and its Complications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1056872716304196?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1056872716304196?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,8]],"date-time":"2018-09-08T11:26:16Z","timestamp":1536405976000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1056872716304196"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2]]},"references-count":19,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,2]]}},"alternative-id":["S1056872716304196"],"URL":"https:\/\/doi.org\/10.1016\/j.jdiacomp.2016.08.017","relation":{},"ISSN":["1056-8727"],"issn-type":[{"value":"1056-8727","type":"print"}],"subject":[],"published":{"date-parts":[[2017,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Following the LEADER \u2013 why this and other recent trials signal a major paradigm shift in the management of type 2 diabetes","name":"articletitle","label":"Article Title"},{"value":"Journal of Diabetes and its Complications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jdiacomp.2016.08.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}